A further retrospective cohort study evaluating 200 patients with HCC receiving in total 425 sessions of intra-arterial therapies (TAE: 13%; TACE: 57%; TOCE: 30%) reported a CR (defined by CT or ...

TACE is a treatment used for hepatocellular carcinoma, the most common type of liver cancer. Experts estimate that 90% or more of liver cancers are hepatocellular carcinomas. While most of your ...

Lenvima plus Keytruda with TACE significantly improved progression-free survival in unresectable, non-metastatic hepatocellular carcinoma compared to TACE with placebo. The study reported a median ...

Japanese researchers sought to build upon prior studies demonstrating the feasibility of liver resection in geriatric hepatocellular carcinoma patients, particularly in those undergoing major ...

In a cohort of 62 patients with HCC there were 141 sessions of TACE with DEB loaded with doxorubicin. [56] At 9 months of follow-up, the sustained objective response (European Association for the ...